Proteomics and Lipidomics Core

蛋白质组学和脂质组学核心（C。Vary，核心总监） 蛋白质组学和脂质组学核心由卡尔文瓦里博士领导，提供高质量的研究设计 支持、样品制备、质谱分析、数据收集和数据分析， 组织和细胞。作为COBRE的一个组成部分，在代谢的间质和神经调节中 自2017年以来，我们的服务一直专注于小鼠和人体组织中的蛋白质和脂质分析。 我们的目标仍然是：1）提供新的方法，扩大以前的蛋白质鉴定能力，2） 为蛋白质组学和脂质组学研究提供公正的分析工作流程，包括3）进一步开发 靶蛋白（例如，MRMHR、SRM）和脂质定量（MSMSALL、MPIS）工作流程，以及4）提供 改进数据解释和确定机制的统计和信息学方法。 在该COBRE的第一阶段，蛋白质组学和脂质组学核心始终支持基础，翻译， 临床研究项目和拨款申请。其中包括年轻的飞行员发起的COBRE 项目，COBRE试点项目和其他NIH研究应用程序，包括MaineHealth内外 研究所。第一阶段的一个重要成就是授予NIH S10共享仪器 资助支持新的高分辨率TripleToF质谱仪，液相色谱仪和其他 支持设备。MaineHealth提供了机构资金来翻新该设施， 在更高效的占地面积中使用现有和新设备。这种支持提高了我们的能力，效率， 通过允许扩展蛋白质组学和脂质组学工作流程并增加用户访问， 为内部和外部用户提供支持正在进行的研究和培训的新机会。同相 我，我们招募了一位杰出的质谱技术经理，卡洛斯加特纳博士，他带来了 专业知识，包括质谱仪器和先进的液相色谱。我们也 招募了Yulica Santos-Ortega博士作为基于质谱的心血管 蛋白质组学经验。新的第二阶段机会包括利用全人类蛋白质组选择 使用在线数据储存库的反应监测协议，将在新仪器上实施 （Sciex QTRAP 6500+）。我们继续保持独特的地位，作为唯一的区域设施， 这些服务用于科学研究，并支持学生，研究人员和工作人员的培训。在这 COBRE，这些资源将是促进初级研究人员晋升的关键。这个核心将推进 我们对产热脂肪细胞谱系的性质和在能量平衡中的作用的理解（项目1， M. Lynes），深入了解X/A细胞分泌蛋白质组在减肥手术相关骨丢失中的作用（项目 2，Z. Li）。这一核心也将很好地支持PI进展和未来的探索方向， 确定心脏代谢疾病中可改变的危险因素（项目3，I. Agarwal）。

Proteomics and Lipidomics Core (C. Vary, Core Director) The Proteomics and Lipidomics Core is led by Calvin Vary PhD and provides high quality research design support, sample preparation, mass spectrometry analysis, data collection, and data analysis for a variety of tissues and cells. As a component of the COBRE in Mesenchymal and Neural Regulation of Metabolic Networks since 2017, our services have focused on protein and lipid profiling in mouse and human tissues. Our goals remain to: 1) provide new approaches that expand previous protein identification capabilities, 2) provide unbiased analytic workflows for proteomics and lipidomics studies that include 3) further developing targeted protein (e.g., MRMHR, SRM) and lipid quantitation (MSMSALL, MPIS) workflows, and 4) provide improved statistical and informatics approaches for data interpretation and identification of mechanisms. In Phase I of this COBRE, the Proteomics and Lipidomics Core consistently supported basic, translational, and clinical research projects and grant applications. These have included young investigator-initiated COBRE projects, COBRE pilot projects, and other NIH research applications, both within and outside of MaineHealth Institute for Research. A significant Phase I accomplishment was the award of an NIH S10 shared instrument grant in support of a new high resolution TripleToF mass spectrometer, liquid chromatograph, and other support equipment. MaineHealth provided institutional funds to renovate the facility, which consolidated the current and new equipment in a more efficient footprint. This support has increased our capacity, efficiency, and flexibility by allowing expanded proteomics and lipidomics workflows and increased user access, while providing new opportunities to support ongoing research and training for internal and external users. In phase I, we recruited an outstanding mass spectrometry technology manager, Carlos Gartner PhD, who brought expertise that includes mass spectrometry instrumentation and advanced liquid chromatography. We also recruited Yulica Santos-Ortega, PhD as a research associate with mass spectrometry-based cardiovascular proteomics experience. New Phase II opportunities include exploitation of human proteome-wide selected reaction monitoring protocols using on-line data repositories that will be implemented on new instrumentation (Sciex QTRAP 6500+). We continue to be uniquely positioned as the only regional facility of its kind providing these services for scientific inquiry and in support of student, investigator, and staff training. Within this COBRE, these resources will be critical for promoting junior investigator advancement. This core will advance our understanding of the properties of thermogenic adipocyte lineages and roles in energy balance (Project 1, M. Lynes), provide insight into the role of the X/A cell secretome on bariatric surgery-related bone loss (Project 2, Z. Li). This core will also be well positioned to support PI progress and future exploratory directions for identification of modifiable risk factors in cardiometabolic disease (Project 3, I. Agarwal).